A fully human streptolysin O-neutralizing monoclonal antibody improves survival in a murine model of group A streptococcus necrotizing soft tissue infection
Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)
DOI: 10.1128/aac.00575-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Emily Price und 12 weiteren Autor:innen. Beteiligte Einrichtung: Boise VA Medical Center, Boise, Idaho, USA. Hauptthemen laut MEDLINE: Streptolysins, Streptococcus pyogenes, Antibodies, Monoclonal, Streptococcal Infections. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Necrotizing soft tissue infections (NSTIs) caused by Streptococcus pyogenes (group A streptococcus [GAS]) are rapidly progressive, toxin-driven infections for which no targeted antitoxin therapies exist. Streptolysin O (SLO), a cholesterol-dependent cytolysin, is a key mediator of tissue injury, vascular occlusion, and immune dysfunction and, thus, represents a promising therapeutic target. Here, we isolated and characterized three fully human monoclonal antibodies (huMAbs) against SLO (C11, G4, and L17) from the memory B cells of a naturally immunized donor using antigen-specific B-cell enrichment. All three huMAbs bound SLO with high affinity and potently neutralized SLO-induced hemolysis in vitro . Mechanistic studies revealed that C11 and G4 inhibited SLO-membrane binding, whereas L17 protected host cells without blocking membrane binding. Despite similar neutralizing potency in vitro , only L17 significantly improved disease outcomes in vivo . In a murine model of GAS-NSTI, L17 reduced clinical disease severity and prolonged survival by approximately 130%. Together, these findings demonstrate that antibody-mediated neutralization of SLO can alter disease outcomes during GAS-necrotizing infection and support the potential of L17 as a clinically relevant antitoxin therapeutic candidate for GAS-NSTI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boise VA Medical Center, Boise, Idaho, USA.
- Idaho State University, Meridian, Idaho, USA.
- Idaho Veterans Research and Education Foundation, Boise, Idaho, USA.
- Idaho State University, Pocatello, Idaho, USA.
- University of Washington School of Medicine, Seattle, Washington, USA.
- Baylor University, Waco, Texas, USA.
ORCID-Profile: Sarah E Hobdey
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Price, E., Nmaju, A., Faozia, S., Lamb, C. L., McIndoo, E. R., Catlin, S., Ayllon, M., Breuer, D. J., Sanders, B., Fologea, D., Stevens, D. L., Bryant, A. E., & Hobdey, S. E. (2026). A fully human streptolysin O-neutralizing monoclonal antibody improves survival in a murine model of group A streptococcus necrotizing soft tissue infection. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00575-26
Vancouver
Price E, Nmaju A, Faozia S, Lamb CL, McIndoo ER, Catlin S, et al. A fully human streptolysin O-neutralizing monoclonal antibody improves survival in a murine model of group A streptococcus necrotizing soft tissue infection. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00575-26
BibTeX
@article{Price2026,
author = {Price, Emily and Nmaju, Anyauba and Faozia, Sabrina and Lamb, Cheri L and McIndoo, Eric R and Catlin, Sydney and Ayllon, Marcelo and Breuer, Dylan J and Sanders, Bryan and Fologea, Daniel and Stevens, Dennis L and Bryant, Amy E and Hobdey, Sarah E},
title = {A fully human streptolysin O-neutralizing monoclonal antibody improves survival in a murine model of group A streptococcus necrotizing soft tissue infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {8},
doi = {10.1128/aac.00575-26}
}
EUVIMED